Latest Videos
What is the optimal timing and sequence for incorporating NGS CGP in cancer patients? At the time of presentation? After failure of neoadjuvant cytotoxic therapy? Are there guidelines or established protocols for a genomically-informed ...
Does FoundationOne’s comprehensive NGS genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Please discuss. Do you know of any other genomic profiling services that are clinically ...
What guidance can you give in those cases in which the F1M CGP profile reveals multiple relevant, actionable mutations? On what basis would you select targeted therapies when multiple significant genomic alterations or rearrangements co-exist?
What have we learned about resistance to molecular targets, for example, in the area of ALK mutations, and how have serial NGS assessments with progressive biopsies helped our understanding of drug resistance and sequential lines of therapies ...
How does NGS vs. “Hot Spot” testing address the fundamental changes that systemic cancer treatment is undergoing, e.g. moving away from a paradigm in which histopathologically-defined disease is treated primarily with cytotoxic chemotherapy, ...
What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with ...
In what types of solid tumors has mutation-directed therapy been shown to improve patient outcomes, including progression-free survival and overall (OS)?
Does FoundationOne’s comprehensive genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Please discuss. Do you know of any other genomic profiling services that are clinically ...
What are the published top-line findings of exploratory studies in which FoundationOne NGS genomic profiling targeting 145 “cancer-relevant”genes is applied to colorectal cancer and gastric cancer?
Why are current genomic testing models based on targeted sequencing (“Hot Spot”) unsustainable and more limited than comprehensive genomic profiling (CGP) developed by FoundationOne?
How does massively parallel (or ‘next-generation’) DNA sequencing overcome the following practical considerations regarding pathological tumor specimens? (1) Using FFPE specimens, a process that may damage DNA? (2) Accommodating limited ...
Since Hot Spot profiling is inadequate for detecting copy number alterations and rearrangements, which critical and actionable tumor-specific molecular targets are likely to be missed by Hot Spot profiling as opposed to CGP and why is ...